Neutron Therapeutics

Executive Summary

Neutron Therapeutics is a private oncology company pioneering Boron Neutron Capture Therapy (BNCT), a novel radiation modality designed to target malignant cells at the cellular level while sparing surrounding healthy tissue. By leveraging the unique properties of boron-10 and neutron irradiation, BNCT enables high-dose, tumor-specific radiation delivery, potentially reducing treatment fractionation to a single session. Founded in 2015 and headquartered in Boston, the company aims to address significant unmet needs in radioresistant and recurrent tumors, where conventional radiotherapy is limited by toxicity. Though still in early clinical development, Neutron Therapeutics represents a promising approach in the precision oncology landscape, capitalizing on decades of BNCT research and recent advances in accelerator-based neutron sources.

Upcoming Catalysts (preview)

• Q4 2026Pivotal Trial Initiation for First Indication60% success
• Q2 2026FDA Breakthrough Device Designation70% success
• TBDStrategic Partnership with Major Cancer Center50% success